Cancer research has undergone unprecedented acceleration in recent years due to advances in molecular biology, immunology, genomics, and artificial intelligence. The period from 2024 to 2025 has been particularly significant, marked by the approval of novel anticancer agents, progress in personalized immunotherapy, rapid development of antibody–drug conjugates, mRNA-based cancer vaccines, liquid biopsy technologies, and AI-driven diagnostics. These innovations have enhanced tumor specificity, improved survival outcomes, and reduced systemic toxicity. This comprehensive review critically evaluates the most recent advancements in cancer research, emphasizing translational relevance, clinical applicability, and emerging challenges such as drug resistance, tumor heterogeneity, and healthcare accessibility. The review aims to provide pharmacy and biomedical researchers with a detailed overview of contemporary oncology research and its future trajectory.
Ms. Mugdha Jagdishbhai Dhimar1*, Ms. Ayushi Sanjaykumar Chokshi2, Mr. Jimitkumar Bharatbhai Prajapati3, Mr. Vandit Ashwinbhai Moradiya4, Mr. Vipul Bhurabhai Chaudhary5, Mr. Dhruv Mukeshbhai Makwana6 (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: